Eikon, Agomab raise $350M total in IPOs, sink in aftermarket: Public Equity Report

All four life sciences companies that priced IPOs this week met or exceeded their expectations, although the two with more innovative products saw their share prices decline in the aftermarket.

It’s a mixed set of signals for the long list of biotechs hoping 2026 will be the year when the IPO window opened up, after a few years of finding other sources of capital while waiting for market conditions to improve...